Marizomib

DB11762InvestigationalSmall molecule

Marizomib has been used in trials studying the treatment of Cancer, Melanoma, Lymphoma, Glioblastoma, and Malignant Glioma, among others.

Mechanism: Pharmacologically active on Proteasome subunit beta type-3
Curator reviewed
Formula / weight: C₁₅H₂₀ClNO₄ · 313.78 g/mol (avg)
Code names: NPI-0052

Resolves to

Compound

Structure

InChIKeyNGWSFRIPKNWYAO-SHTIJGAHSA-NSMILESC[C@@]12OC(=O)[C@@]1(NC(=O)[C@@H]2CCCl)[C@@H](O)[C@H]1CCCC=C1

Targets

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

12Clinical trialsPhase, status and sponsor resolved per trial

11+ReferencesStructured and connected to the statements they support

Which drugs share a target with Marizomib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.